[Prospect of hepatocellular carcinoma in 2008].
Ye
Sheng-Long
SL
Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China. slye@shmu.edu
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000494:pharmacology / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000601:surgery / Q000628:therapy*; D003937:Diagnosis, Differential; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000601:surgery / Q000628:therapy*; D016031:Liver Transplantation; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009536:Niacinamide / Q000031:analogs & derivatives; D020411:Oligonucleotide Array Sequence Analysis; D010671:Phenylurea Compounds; D016133:Polymerase Chain Reaction; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D012189:Retrospective Studies; D000077157:Sorafenib; D015996:Survival Rate
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib